VMD’s Q2 2026: Viemed’s Revenue Forecast Rises as Home-Health Ventilation Gains Momentum

Viemed Healthcare, Inc. — traded on the NASDAQ under the ticker VMD — reported second-quarter 2026 results that sweetened the company’s revenue forecast and highlighted a still-healthy EPS profile in a growing, less-capital-intensive mix of services. The quarter delivered a concrete reminder that in the world of technology-enabled, home-based healthcare, momentum in ventilator-related services can move the top line while cash flow remains a focus.

The Numbers: A Quarter of Growth, a Draft of Guiding Light

For the quarter ended June 30, 2026, Viemed posted net revenues of $78.1 million, a record for the company, up 23.9% year over year and up about 3.6% sequentially. The growth was broad enough to lift the revenue forecast for the full year; management now expects net revenue between $314 million and $320 million, a modest push higher from prior guidance.

Diluted earnings per share (EPS) stood at $0.07 for the quarter, as net income attributable to Viemed totaled $2.8 million. The press release frames this as a stable EPS result against the backdrop of a prior-year non-recurring gain that skewed year-over-year comparisons—specifically a $1.0 million gain related to a ventilator-return program that did not recur in 2026. In other words, chip away the one-off and the underlying EPS story remains orderly.

Adjusted EBITDA for the quarter was $13.7 million, a 4.0% decrease versus the June 2025 quarter. The comparison is anchored by the non-recurring gain in the prior year, which means the year-over-year delta isn’t purely a function of operating performance this time around. Viemed notes that the prior period included that $1.0 million non-recurring gain on disposal of property and equipment; excluding that item, the trajectory would be less headwind-laden.

Cash flow and liquidity metrics remained healthy for a midsize healthcare company. Net cash provided by operating activities totaled $15.9 million for the quarter and $60.8 million for the trailing twelve months. Free cash flow reached $8.6 million for the quarter and $34.4 million for the trailing twelve months. The company ended the quarter with roughly $10.7 million in cash and $6.1 million in working capital; debt metrics show long-term debt at $6.4 million and $46 million available under existing credit facilities. As a sign of capital discipline, Viemed repurchased and canceled 530,802 shares for $5.1 million at an average price of $9.65 per share.

On a patient care basis, Viemed reported 12,635 ventilator patients at quarter-end, up 4.0% from June 30, 2025, and a 4.5% sequential increase from March 31, 2026. PAP therapy patient counts rose to 37,825 (up 44.0% YoY) and sleep resupply patients were 37,035 (up 46.7% YoY), with sequential increases as well. The underlying pattern suggests continued demand for home-based, technology-enabled care across ventilator and sleep-disorder management.

Guidance and the Non-GAAP Frame

Viemed reiterated guidance that emphasizes a shift toward a higher contribution from less capital-intensive product and service revenue. In the aggressive language of corporate updates, the company notes a “revised guidance” posture: net revenue guidance is nudged up, and the Adjusted EBITDA range is tightened to reflect evolving mix and cost discipline.

Net revenue: now expected in a $314 million to $320 million range (up from $312 million to $320 million).
Adjusted EBITDA: now anticipated to run between $64 million and $68 million (versus the prior $65 million to $69 million).
Net capital expenditures: projected to be 8.5% to 10.0% of net revenue (versus 9.0% to 10.5% previously).

The company also points to the use of non-GAAP financial measures and guidance, inviting readers to review the “Use of Non-GAAP Financial Information and Financial Guidance” section for details. For investors, this means EPS consistency and revenue trajectory will be read through both GAAP and non-GAAP lenses as 2026 unfolds.

Analysts’ EPS consensus has not been enumerated in the release, but the higher revenue forecast and stable EPS print in a quarter buoyed by a solid cash-generative profile are likely to influence expectations. The absence of a dramatic earnings surprise should be read as a sign that Viemed’s quarter aligns with its stated path and that the updated revenue forecast is a meaningful shift, not a one-off flare.

Why This Matters: The Viemed Thesis and What It Portends

The standout takeaway is not just a higher top-line target, but a narrative about portfolio mix. The press release emphasizes growth from ventilation and broader platform services—areas that tend to offer more sustainable cash flow and lower capital intensity than hardware-heavy segments. The cash-flow machine continues to hum, even as debt remains modest and liquidity is ample to fund buybacks and potential smaller acquisitions or working-capital needs.

For Viemed’s sector peers, the message is twofold. First, the market appears to reward firms that can convert patient scale into recurring revenue through services and consumables, not just equipment sales. Second, disciplined capital allocation—evidenced by a $5.1 million share repurchase and a modest debt footprint—remains a credible playground for value-centric investors in the fragmented home-health technology space.

From a competitive standpoint, peers that can demonstrate a similar ramp in ventilator-based care and sleep-related services—with evidence of durable cash generation—may see a positive re-rating of earnings quality. The absence of a negative earnings surprise, combined with a higher net revenue target, should support a constructive read on near-term earnings trajectory and help set a floor for sector-wide multiple expansion.

Risks and Forward-Looking Notes

Investors should note that all guidance is subject to the usual caveats: macro conditions, regulatory environments, payer dynamics, and the ongoing integration of service lines could affect both revenue mix and costs. The shift toward less capital-intensive revenue, while favorable to cash flow, could also alter gross margin dynamics if service components carry different margin profiles than equipment-based products.

In addition, the company’s leverage is modest, and cash on hand is meaningful but not large relative to the enterprise scale. Any acceleration in capex or working capital needs would impact free cash flow generation and the company’s ability to fund buybacks at current levels.

Bottom Line: A Positive Recalibration, With Watchful Eyes on the EPS Narrative

Viemed’s Q2 2026 results present a coherent, positive signal: revenue growth is broadening, the company nudges its full-year revenue forecast higher, and cash-generation metrics remain robust enough to support a measured share-repurchase cadence. The EPS print of $0.07 per diluted share sits alongside an updated revenue forecast that reflects a favorable mix shift toward services and less capital-intensive revenue.

For investors following VMD and peers in the home-health technology space, the implication is clearer: those who can sustain above-market growth through service-based revenue and maintain tight capital discipline stand a better chance of translating quarterly momentum into earnings stability. The earnings surprise risk appears to be contained for now, and the EPS consensus may tilt higher as analysts reconcile the revised outlook with growth dynamics in ventilator care and sleep-disordered management.

In the rumor mill of quarterly disclosures, Viemed just handed sector watchers a clean script: a solid quarter, a higher 2026 revenue target, and a plan to fund that plan with cash flow and judicious buybacks. The next act will hinge on whether this momentum persists into the second half of the year and how the broader healthcare environment interacts with a home-based care model that increasingly leans on technology-enabled services rather than hardware alone.